Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01147666 · ClinicalTrials.gov registry record · Phase 2
Study of Roxadustat (FG-4592) in Participants With End-Stage Renal Disease Receiving Maintenance Hemodialysis
A Phase 2 study, sponsored by Kyntra Bio.
- Completed
- Registry status
- Phase 2
- Development phase
- 161
- Enrollment target
NCT01147666 is a Phase 2 study that has completed, run by Kyntra Bio. The registered enrollment target is 161 participants.
The verdict
NCT01147666, a Phase 2 study, has completed, sponsored by Kyntra Bio.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 161 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate the efficacy and safety of roxadustat in participants with end-stage renal disease (ESRD) on maintenance hemodialysis (HD) therapy, previously treated with intravenous (IV) epoetin alfa.
Interventions
- OTHER Placebo
- DRUG Epoetin Alfa
- DRUG Roxadustat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 161 participants |
| Start Date | 2010-05-17 |
| Est. Completion | 2012-10-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01147666
The ClinicalTrials.gov registry entry for NCT01147666 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 161 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kyntra Bio, which has 30 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01147666 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01147666 about?
NCT01147666 is a clinical study titled "Study of Roxadustat (FG-4592) in Participants With End-Stage Renal Disease Receiving Maintenance Hemodialysis". The primary objective of this study is to evaluate the efficacy and safety of roxadustat in participants with end-stage renal disease (ESRD) on maintenance hemodialysis (HD) therapy, previously treated with intravenous (IV) epoetin alfa.
What is the current status of trial NCT01147666?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 161 participants. The study started on 2010-05-17. Estimated completion is 2012-10-15.
What interventions are being tested in trial NCT01147666?
The interventions under investigation include: Placebo (OTHER), Epoetin Alfa (DRUG), Roxadustat (DRUG).
Who is sponsoring clinical trial NCT01147666?
This trial is sponsored by Kyntra Bio, which has 30 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.